| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911237 | Lung Cancer | 2013 | 6 Pages |
Abstract
Despite similar outcomes, GEMVIN was more expensive than PV or PG in 2005 because of higher chemotherapy costs. By 2013, after chemotherapy drug patent expiry, GEMVIN became the least costly regimen. Economic considerations in oncology change over time, and should be revisited in policy decisions based on cost.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Neil Reaume, Natasha B. Leighl, Nicole Mittmann, Doug Coyle, Vera Hirsh, Lesley Seymour, Dongsheng Tu, Frances A. Shepherd, Barbara Graham, Cesare Gridelli, Francesco Perrone, Massimo Di Maio, Penelope A. Bradbury, William K. Evans,